Execs On The Move: Management Changes At Sphingotec And Rockwell Medical; New Chair At Orexo
A new COO joined the management team at German biomarker company Sphingotec; Rockwell Medical, a producer of kidney disease therapies, picks a CEO; Orexo AB, a developer of proprietary drug delivery technology, gets new board chair; and more.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.